Immune cells engineered to hunt brain tumors in kids

NCT ID NCT07087002

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack tumor cells, delivered directly into the fluid around the brain. The main goals are to see if the cells can be made safely and to find the best dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR (ATRT) OF THE CNS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical teratoid rhabdoid tumor brain cancer central nervous system primitive neuroectodermal neoplasm cerebral neuroblastoma childhood central nervous system primitive neuroectodermal neoplasm cns neuroblastoma with FOXR2 activation embryonal tumor with multilayered rosettes medulloblastoma Neuroectodermal Tumors, Primitive Pinealoma pineoblastoma rhabdoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATYPICAL TERATOID/RHABDOID TUMOR (ATRT) OF THE CNS CENTRAL NERVOUS SYSTEM EMBRYONAL TUMOR CNS NEUROBLASTOMA EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES (ETMR) FOXR2-ACTIVATED MEDULLOBLASTOMA PEDIATRIC BRAIN TUMOR PINEOBLASTOMA RECURRENT MEDULLOBLASTOMA REFRACTORY MEDULLOBLASTOMA

Contacts and locations

Locations

Lucile Packard Children's Hospital Stanford
RECRUITING

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.